Skip to main content
Article
PRE-binding sites in the MDR of CLL: Potential Tumor Suppressor Regulation
Advances in Bioscience and Biotechnology
  • Christine E. Cutucache, University of Nebraska at Omaha
  • Javeed Iqbal, University of Nebraska Medical Center
  • Philip Bierman, University of Nebraska Medical Center
  • Robert Gregory Bociek, University of Nebraska Medical Center
  • Dennis D. Weisenburger, University of Nebraska Medical Center
  • Shantaram S. Joshi, University of Nebraska Medical Center
Document Type
Article
Publication Date
1-1-2013
Disciplines
Abstract
Chronic lymphocytic leukemia [CLL] is the most common adult leukemia and is heterogeneous in clinical presentation. CLL cases present with various chromosomal aberrations, including 11q23, 14q32, 17p, and trisomy 12, with the most common abnormality being deletion of 13q14 [1]. Although monoallelic deletion of 13q14 is common, there is a subset of patients who have complete nullisomy at 13q14, a locus that has been hypothesized to contribute to CLL pa thogenesis [2] due to loss of tumor suppressors [DLEU and miR-15a/16-1].We hypothesized that deletion of both copies of 13q14 would lead to uncontrollable proliferation of CLL cells and a poor prognosis. We examined our 13q14 nullisomy for survival, treatment-free survival, lymphocyte doubling time, and the presence of lymphadenopathy. Furthermore, we compared the gene expression profiles between patients with 13q14 monosomy, nullisomy, or normal karyotype. Our results suggest that patients with 13q nullisomy have a higher incidence of bulky lymphadenopathy [16.6% compared to 10% of monosomy patients], a higher frequency of lymphocyte doubling time [27.7% compared to 7.4% of monosomy patients], and a higher rate of needing treatment [50% compared to 18.5% of monosomy patients]. We observed deletion of DLEU1 and HTR2A, consistent with a gene dosage effect, and observed PRE-binding sites on DLEU1. Patients with homozygous deletion of 13q14 had a worse prognosis compared to heterozygotes. Lastly, the DLEU1 locus is a possible “second hit” loss for CLL progression.
Comments

Copyright © 2013 by author(s) and Scientific Research Publishing Inc.

Citation Information
Christine E. Cutucache, Javeed Iqbal, Philip Bierman, Robert Gregory Bociek, et al.. "PRE-binding sites in the MDR of CLL: Potential Tumor Suppressor Regulation" Advances in Bioscience and Biotechnology Vol. 4 Iss. 1A (2013) p. 129 - 135
Available at: http://works.bepress.com/christine-cutucache/9/